Some hepatitis C patients -- especially women -- don't really benefit from early therapy.
Levenson
Deborah
D
D003362:Cost-Benefit Analysis; D018450:Disease Progression; D005260:Female; D006526:Hepatitis C / Q000191:economics / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012737:Sex Factors; D016896:Treatment Outcome; D014481:United States; D014930:Women
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin